RegASK Raises $10M in Series A Funding to Accelerate Growth

Regask Raises $10m In Series A Funding To Accelerate Growth

SINGAPORE, December 15, 2022 — RegASK, a global RegTech company that uses an AI-powered SaaS platform to help businesses manage regulatory compliance, announced today that it has raised $10 million in Series A funding. The round is led by venture capital firm Monograph Capital and joined by SPRIM Global Investments and other investors. The financing allows RegASK to further invest in the SaaS platform to strengthen its capabilities and assist more companies around the world to achieve their regulatory compliance goals.

RegASK completed a seed round investment in early 2019 and has since been executing its ambitious growth strategy and product development plan. Leveraging artificial intelligence (AI), RegASK’s technology platform routinely monitors regulatory changes in the biopharma, medical device, decentralized clinical trials, consumer health, cosmetics, and food industries. It provides users with curated regulatory intelligence summarizing the regulatory changes and implications for their businesses, allowing them to stay ahead of the fast-changing regulatory environment and remain compliant.

In addition, RegASK has a global network of 400+ subject matter experts in 100+ countries who provide in-depth insights into existing regulations and potential regulatory changes in local markets. CROs, biopharma, medical device, consumer health, and food companies benefit enormously from RegASK’s services, as RegASK makes regulatory information relevant, curated, and easy to access for businesses, enabling them to cut through the clutter and complexity of an ever-growing number of new regulations.

“The addition of Monograph Capital is strategic to RegASK’s development roadmap,” said Caroline Shleifer, PhD, CEO of RegASK. “RegASK AI-powered platform offers companies an innovative and user-friendly solution to reduce their regulatory monitoring and compliance burdens. Monograph’s leadership brings deep industry understanding of the needs of life science and CRO companies.”

Charles Conn, Monograph Partner, said, “RegASK is a wonderfully innovative approach to the burgeoning regulatory strategy and compliance space, applying AI to streamline information capture and planning for pharmaceutical companies, clinical research organizations and many other segments. Monograph is excited to be part of the company’s growth path.”


About RegASK

Founded in 2018, RegASK is a RegTech SaaS platform that enables businesses to leverage AI to scale their regulatory and compliance capabilities. With RegASK, businesses can easily access relevant regulatory information automatically identified and curated. Always up to date through automatic RegAlert™, the platform further provides RegInsight™ on regulatory trends and development, as well as access to a network of 400+ subject matter experts in over 100+ countries to help companies navigate the international and local regulatory landscape.


About Monograph

Monograph Capital is a life sciences venture firm based in London and San Francisco, with investments in breakthrough therapeutics, diagnostics, and digitally-enabled healthcare to improve the practice of medicine.


Original source of the press release:

RegASK announces US$10m Series A Funding Round led by Monograph Capital to accelerate its growth

Have a
regulatory affairs

Regulatory Affair Icon